Faronin Petri Bono-jakso syövän ennaltaehkäisystä, varhaisesta havaitsemisesta ja hoitojen tulevaisuudesta Spotifyssa: open.spotify.com/episode/4IyWlq…

Excellent News for breast cancer patients. A paradigm shift for HR-positive disease with HER2-low or ultralow expression.

Brave head to head trial. Result showed Eli Lilly’s tirzepatide was superior to Novo’s semaglutide for weight loss. First direct clinical conparison between these two leading obesity drugs.

Our Dr. Naval Naval Daver, M.D. shared an encouraging safety profile for the first-in-class macrophage checkpoint inhibitor, bexmarilimab, in combination with azacitidine for treatment of higher-risk myelodysplastic syndrome in both the frontline and refractory/relapsed settings.

Cancer vaccines will be a big part of the future of immunotherapy. A new, super review The Lancet thelancet.com/journals/lance…

Another step closer to a multicancer early detection test — a long-time dream of patients and oncologists. Ongoing randomized trial results are eagerly awaited. Cancer May Be Detectable in Bloodstream 3 Years Prior to Diagnosis - The ASCO Post ascopost.com/news/june-2025…

From New York Times today: Reduced Screening May Have Led to Rise in Advanced Prostate Cancer Diagnoses nytimes.com/2025/09/02/hea…

The #ESMO25 Presidential are out--check them: FabriceAndre Myriam Chalabi ESMO - Eur. Oncology

Cancer deaths expected to rise to over 18 million in 2050—an increase of nearly 75% from 2024, study forecasts. Explore the data ▶️ hubs.li/Q03KY9qR0 Institute for Health Metrics and Evaluation (IHME) #NCDs

Data presented at #ESMO25 by Dr Mika Kontro on the Macrophage reprogrammer #bexmarilimab plus azacitidine in myelodysplastic syndrome (BEXMAB) ESMO - Eur. Oncology OncoAlert Naval Daver, M.D. Amer Zeidan MBBS,MHS ‏عامر زيدان

Tom is changing bladder cancer SOC, one ESMO - Eur. Oncology and ASCO meetings (twice/year) ….with concomitant NEJM publications! No surprise that Pr. Tom Powles is Top 10 nature people !

Greetings from last week’s #ESMO congress - this is exciting! The power of immune system. People with some cancers (melanoma and lung cancer)live longer after a COVID vaccine. Confirmatory phase 3 ongoing. nature.com/articles/d4158…

Which #ASH2025 ASH #MDSsm talk do you look forward to listening to the most?

.Amer Zeidan MBBS,MHS ‏عامر زيدان presents updated results from the #bexmab phase 1/2 study at 2:15pm in the Valencia Room W415B #ASH25. submit.hematology.org/program/presen… Smilow Cancer Hospital Yale Hematology Oncology Fellows YaleHematology ASH

Great presentation by Amer Zeidan MBBS,MHS ‏عامر زيدان of Bexmarilimab- 1st in class Clever-1 Ab- w/ Aza in 1L & R/R HR- MDS w/enrichment for TP53m. Impressive data both in 1L & R/R MDS. Privilege to enroll on this study UNC Lineberger & looking forward to next steps. ASH #ASH2025

The one and only Mika Kontro ⁦Kontro Lab⁩ presenting Bexmarilimab transfusion indepedence and hematological improvement data at #ASH25 poster session.

#ASH25 #BEXMAB study (bexmarilimab : CPI targets CLEVER-1) in HR-MDS. Phase 1/2: showing encouraging result in RR MDS including #TP53m. Data presented by Dr. Amer Zeidan 👏👏👏 #mdssm

Brian Ball on Higher-Risk MDS Bexmarilimab and Azacitidine - The ASCO Post ascopost.com/videos/ash-202…

Faron käynnistää syöpätutkimuksen Britanniassa kauppalehti.fi/uutiset/kl/bad…

🧬 2025 FDA approvals: oncology still leads—but with a shifting mechanistic profile • Oncology dominates approvals: 16/46 (35%) new FDA drugs in 2025 were cancer therapies—well above any other therapeutic area, reinforcing oncology as the primary engine of regulatory innovation.